Corcept Therapeutics (CORT) Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $75.59 -7.74%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $103.4 million versus the consensus estimate of $100.62 million.
GUIDANCE:
Corcept Therapeutics sees FY2022 revenue of $400-430 million, versus the consensus of $414.4 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
- Corcept Therapeutics (CORT) PT Raised to $173 at Piper Sandler
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
